AbbVie’s Q2 2024 Results Show Resilience Amid Humira Biosimilar Challenges
AbbVie Inc. (NYSE: ABBV) has reported its financial results for the second quarter of 2024,...
Finanical Reports
Roche’s H1’24 Financials Show 5% Growth, Eye Care and Cancer Therapies Drive Sales
Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO), the Swiss pharmaceutical and diagnostics giant, has reported...
AstraZeneca’s Q2 2024 Results Highlight Strong Growth Across Therapies, Excluding Vaccines
AstraZeneca (NASDAQ: AZN), a UK-based biopharmaceutical company, has reported its financial results for the second...
Sanofi’s Q2 2024 Results Showcase Robust Growth in Pharma and Consumer Health Divisions
Sanofi (NASDAQ: SNY; EPA: SAN), the French multinational pharmaceutical company, has reported its financial results...
Novartis Delivers Strong Q2 2024 Results with 11% YoY Net Sales Increase
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has released its financial results for the second...
J&J Halts Development of Epilepsy Therapy ADX71149 After Phase II Trial Failure
Johnson & Johnson (J&J; NYSE: JNJ), a US-based multinational medical devices, pharmaceutical, and consumer packaged...
Abbott Laboratories Reports Q2 2024 Sales Growth of 9.3%, Led by Medical Devices and Diabetes Sales
Abbott Laboratories (NYSE: ABT), a global healthcare giant based in the US, has reported its...
Johnson & Johnson Reports Robust Q2 2024 Earnings, Bolstered by Pharma and Medtech Growth
Johnson & Johnson (NYSE: JNJ) has reported its financial results for the second quarter of...
Jiangsu Hengrui Pharmaceuticals Faces FDA Setback with Warning Letter for Quality Control Issues
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a prominent player in China’s pharmaceutical industry, has received a...
Abbisko Therapeutics Forecasts Profits and Revenue Boost in H1 2024 on Merck Deal
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has released a positive financial...
MicroPort Scientific Corp’s Subsidiaries Forecast Significant H1 2024 Revenue Growth
MicroPort Scientific Corp (HKG: 0853), a leading medical device company, has seen its subsidiaries Shanghai...
Bayer’s Q1 2024 Report Shows Slight Dip in Sales Amid Pharmaceutical Unit’s Growth
Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2024,...
Novo Nordisk’s Bispecific Antibody Mim8 Achieves Milestone in Haemophilia A Trial
Novo Nordisk (CPH: NOVO-B), a pharmaceutical company based in Denmark, has announced that its bispecific...
Viatris Q1 2024 Results Show Slight Dip in Base Business Brands Amid Overall Stabilization
US pharmaceutical company Viatris (NASDAQ: VTRS) has reported its financial results for the first quarter...
Takeda’s Fiscal 2023 Revenues Grow 1.5%, CEO Weber Forecasts 2025 Profitability After 2024 Dip
Takeda’s (TYO: 4502) annual report for the fiscal year ended March 31, 2024, has been...
Sandoz Q1 2024 Results Highlight 6% Growth, Led by Biosimilars and European Strength
Switzerland-based Sandoz (SWX: SDZ) has reported its financial results for the first quarter of 2024,...
Novo Nordisk’s Q1 2024 Global Sales Surge 24% YOY on Strength of GLP-1 Therapies
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) reported a substantial 24% year-on-year (YOY) increase in...
Zai Lab’s Q1 2024 Revenue Rises 43% YOY on Strong Product Launch and NRDL Inclusion
Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) has announced its financial results for the first...
BeiGene’s Q1 2024 Revenue Jumps 68% YOY on Strength of Brukinsa and Tislelizumab Sales
BeiGene, Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has released its financial results for the...
Organon’s Q1 2024 Revenues Rise 7% YOY, Women’s Health and Biosimilars Lead the Way
Organon (NYSE: OGN), a leading women’s health specialist, announced a 7% year-on-year increase in revenues...